Non-GAAP modified net product and providers income from our Professional Diagnostics segment was $601.1 million in the fourth quarter of 2013, in comparison to non-GAAP adjusted net product and providers revenue of $584.9 million in the fourth quarter of 2012. Recent professional diagnostics acquisitions contributed $27.2 million of incremental net revenue compared to the fourth quarter of 2012, offset by a reduction in revenue of $6.3 million related to dispositions in the one fourth. North American influenza product sales reduced to $20.9 million for the fourth quarter of 2013, from $23.0 million for the fourth quarter of 2012.Low, medium, and high doses of clonidine led to an increase in TFL of 16 %, 24 %, and 47 % over baseline respectively. The analgesic effect was blocked by microinjection of the a2-adrenergic antagonist idazoxan into the CeA ahead of clonidine, or by intraperitoneal injection of the a2-adrenergic antagonist, yohimbine, to clonidine prior. The analgesia was not present if the shots were moved fractions of a millimeter to various other nearby brain nuclei.